Cargando…

Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL); it has a cure rate of approximately 50% with standard anthracycline-based chemoimmunotherapy. However, the clinical outcomes of elderly unfit/frail DLBCL patients remain suboptimal due to poor tolerance of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yohannan, Binoy, Rios, Adan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482608/ https://www.ncbi.nlm.nih.gov/pubmed/37692866 http://dx.doi.org/10.14740/jh1144

Ejemplares similares

Primary Diffuse Large B-Cell Lymphoma of the Bone
por: Yohannan, Binoy, et al.
Publicado: (2023)

Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin
por: Yohannan, Binoy, et al.
Publicado: (2022)

P1660: THROMBOSIS RISK IN PATIENTS WITH ACUTE LEUKEMIA (AL)
por: Yohannan, Binoy, et al.
Publicado: (2023)

Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies
por: George, Binsah S., et al.
Publicado: (2022)

Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy
por: Kuhlman, Justin, et al.
Publicado: (2021)

Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
por: Wang, Jing, et al.
Publicado: (2022)

Synchronous Presentation of Autoimmune Hepatitis and Multiple Myeloma
por: Yohannan, Binoy, et al.
Publicado: (2022)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL
por: Yohannan, B., et al.
Publicado: (2022)

Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy
por: Chu, Michael P., et al.
Publicado: (2016)

Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)
por: Markovic, O., et al.
Publicado: (2012)

Paraneoplastic Necrotizing Myelopathy in a Patient With Newly Diagnosed Diffuse Large B Cell Lymphoma
por: Lee, Chau Hung, et al.
Publicado: (2011)

Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
por: Yoshida, Masahiro, et al.
Publicado: (2021)

(18)F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study
por: Minamimoto, Ryogo, et al.
Publicado: (2021)

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
por: Abuelgasim, Khadega A., et al.
Publicado: (2019)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma
por: Ladetto, Marco, et al.
Publicado: (2021)

Anthracycline Cardiotoxicity in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report
por: Teixeira da Silva, Francisco, et al.
Publicado: (2020)

Synchronous Diagnosis of Squamous Cell Carcinoma of the Lung and Mixed Cellularity Hodgkin Lymphoma of the Nasopharynx
por: Yohannan, Binoy, et al.
Publicado: (2022)

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement
por: Lehners, Nicola, et al.
Publicado: (2017)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma
por: Linton, Kim, et al.
Publicado: (2020)

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial
por: Hochberg, Jessica, et al.
Publicado: (2022)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023)

Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study
por: Chuang, Tzer-Ming, et al.
Publicado: (2021)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
por: Al-Sarayfi, Diana, et al.
Publicado: (2022)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2016)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Relapse in patients with limited‐stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow‐up of a phase 2 study
por: Kim, Sung‐Yong, et al.
Publicado: (2022)

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
por: Batlle-López, Ana, et al.
Publicado: (2016)

Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma
por: Ewers, Evan C., et al.
Publicado: (2016)

Long-Term Complete Remission of a Patient With Double-Hit Diffuse Large B-Cell Lymphoma Treated by Chemoimmunotherapy and Chinese Herbal Medicine
por: Liang, Henry, et al.
Publicado: (2023)

Fatal Balamuthia mandrillaris Encephalitis
por: Yohannan, Binoy, et al.
Publicado: (2019)

A Nonpediatric Extraosseous Ewing Sarcoma of the Pancreas: Differential Diagnosis and Therapeutic Strategies
por: Yohannan, Binoy, et al.
Publicado: (2020)

B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics
por: Yohannan, Binoy, et al.
Publicado: (2022)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma
por: Zhang, Mu-Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h0phdd9cea7fqglgjnslqld61i